What's Happening?
Jyong Biotech Ltd., a Taiwan-based biotechnology company, has been awarded the Innovation Gold Award in the pharmaceutical category at the 2025 Taipei Biotech Awards. The award recognizes the company's development of BOTRESO®, an oral plant-derived investigational new drug aimed at treating benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS). The award, presented by Taipei City Mayor Wayne Chiang, includes a cash prize of over US$26,000. BOTRESO® has completed four Phase III clinical trials in the United States and Taiwan and is the first Taiwan-developed oral botanical new drug to receive U.S. FDA Investigational New Drug approval and advance into Phase III clinical trials.
Why It's Important?
The recognition of Jyong Biotech's BOTRESO® highlights the growing importance of plant-derived pharmaceuticals in the global healthcare market. This award not only validates the company's research and development efforts but also underscores Taiwan's emerging role in biotech innovation. The successful clinical trials and FDA approval position BOTRESO® as a potential game-changer in the treatment of urinary system diseases, offering a new therapeutic option for patients worldwide. The award may enhance Jyong Biotech's reputation and open doors for further international collaborations and market expansion.
What's Next?
Jyong Biotech plans to continue its efforts to expand its global presence and deliver innovative botanical drugs to meet critical healthcare needs. The company is likely to focus on the commercialization of BOTRESO® in the U.S., EU, and Asian markets, leveraging its proprietary platform and strong research capabilities. The successful completion of the New Drug Application process with the U.S. FDA could lead to BOTRESO® becoming widely available, potentially transforming treatment options for BPH and LUTS.
